All In Biotech

Drug Trial Radar · NCT02703896

Prophylaxis for Aspiration of Gastric Contents.

"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery.

Last checked: Nov 19, 2026Latest source record: Mar 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,920 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,920

Actual

Start

Jan 2012

Primary completion

Jan 2012

Study completion Dec 2015

Sponsor

Lead sponsor
King Saud UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 15 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone, metoclopramide and erythromycin on intragastric pH, volume and bile refluxate.

Conditions

  • Pulmonary Aspiration of Gastric Contents

Interventions

  • Drug either PPIS or H2RA and prokineticsDrug

    Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups 1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 ) 2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10) 3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10) 4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg) 5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10) 6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10) 7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10) 8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10) 9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10) 10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)

  • orogastric intubationProcedure

    OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pH of gastric contentsTime frame: Immediate after induction of general anaesthesia

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.